SOUTH WINDSOR, Conn., Feb. 03, 2017 -- Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM™), today announced that it has closed on an additional round of strategic investment from Hexcel Corporation (NYSE:HXL). In May 2016, OPM and Hexcel announced an initial strategic investment from Hexcel of $15 million. The second round of investment from Hexcel is $10 million, for a total equity investment of $25 million to date.
OPM develops proprietary material, process and application technologies, and its Aerospace & Industrial business unit applies 3D printing technology and HPAM™ to produce fully functional end-use parts that combine structural strength, enhanced performance, weight reduction and time-to-market benefits for its customer base.
Hexcel is a global leader in advanced composites technology with headquarters in Connecticut and manufacturing locations worldwide. OPM Aerospace & Industrial utilizes Hexcel carbon fiber in the production of OPM’S 3D printed OXFAB®–ESD advanced thermoplastic structural parts for its aerospace, satellite & defense programs.
OPM recently announced its contract award from Boeing to supply 3D-printed OXFAB® structural production parts for the CST-100 Starliner. Hexcel’s follow-on investment will further enable OPM to expand capacity to meet rapidly growing market demand for the company’s OXFAB® technology in aerospace and other industries.
About Oxford Performance Materials, Inc.
A recognized leader in advanced materials science, Oxford Performance Materials Inc. (OPM) was founded in 2000 to exploit and commercialize the world’s highest performing thermoplastics, with a focus on poly-ether-ketone-ketone (PEKK). OPM develops proprietary material, process and application technologies and applies high performance additive manufacturing (HPAM™) to produce fully functional end-use structural parts. The Company has three strategic business units: OPM Materials develops proprietary OXPEKK® thermoplastic products and other materials for biomedical, aerospace and industrial applications. OPM Aerospace & Industrial produces 3D printed OXFAB® production parts for highly demanding aerospace, satellite and defense applications. OXFAB® structures offer significant weight, cost and time-to-market reductions that are defined in a set of specified performance attributes in the exhaustive OPM B-Basis database, developed in conjunction with NASA. OPM Biomedical is a pioneer in personalized medicine, 3D printing OsteoFab® cranial and facial implants as an OEM, and its SpineFab® line on a contract manufacturing basis. OPM Biomedical is the first and only company to receive FDA 510(k) clearance to manufacture 3D printed patient-specific polymeric implants, and has a total of four 510(k) clearances in its portfolio. For more information, please visit: www.oxfordpm.com
Company Contact: Bernie Plishtin Oxford Performance Materials 860-656-9446 [email protected] Media Contact: Cory Ziskind ICR 646-277-1232 [email protected]


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
FDA Approves Mitapivat for Anemia in Thalassemia Patients
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 



